• Citer

The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas

par Abele, Reto;Clavel, Michel;Dodion, Pierre ;Bruntsch, Utta;Gundersen, Stein;Smyth, John;Renard, Josette;van Glabbeke, Martine;Pinedo, Herbert H.M.
Référence European journal of cancer & clinical oncology, 23, 12, page (1921-1924)
Publication Publié, 1987-12

Article révisé par les pairs

• Détails
• Contenu

Résumé :

The Early Clinical Trials Cooperative Group of the EORTC conducted several phase II studies with a pyrimidine analogue of deoxycytidine, 5-aza-2′-deoxycytidine (DAC). The drug was given as three consecutive 1 h i.v. infusions of 75 mg/m2, separated by intervals of 7 h; courses were repeated every 5 weeks. A total of 101 eligible patients were studied: 42 with colo-rectal adenocarcinoma, 27 with squamous cell carcinoma of the head and neck, 18 with malignant melanoma and 14 with renal cell carcinoma. Drug-induced toxicities consisted of moderate myelosuppression, and nausea and vomiting. One single partial remission was seen in a patient with malignant melanoma. DAC given in this dose and schedule is devoid of antitumour activity in adult patients with these refractory types of carcinomas. © 1987.